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Abstract
Schizophrenia is a chronic and disabling disor-
der, characterized by positive, negative, cognitive
and affective symptoms. The first episode of
schizophrenia (FES) usually occurs after a vari-
able period of prodromic symptoms and the im-
portance of early detection and treatment of FES
has been raised in psychiatric literature from long
time. In fact, it has been suggested that the first
years of the schizophrenic disorder may be a crit-
ical period for long-term prognosis, as the rela-
tionship between the poor medication adherence
and poorer outcome is well demonstrated. Long-
acting injectable formulations of second-genera-
tion antipsychotics (SGAs-LAIs) provide constant
medication delivery and the potential for im-
proved adherence. Currently, four SGAs-LAIs are
available for the treatment of schizophrenia,
risperidone long-acting injectable, olanzapine
pamoate, paliperidone palmitate and aripiprazole.
Several studies have also demonstrated efficacy
and safety of such drugs in patients with schizo-
phrenia. In the present paper the literature on
SGAs-LAIs atypical antipsychotics in the treat-
ment of FES will be reviewed and practical advice
will be given concerning the use of this drug in
the everyday clinical practice.
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Introduction
Schizophrenia is a chronic and disabling disorder,
characterized by positive, negative, cognitive, and af-
fective symptoms (1-3). The course of schizophrenia
may be complicated by the potential occurrence of
suicidal and/or violent behaviors, substance abuse
and medical comorbidity, with sustained morbidity
and disability that may severely impair quality of life
of patient and shorten their lives (4-6). The first
episode of schizophrenia (FES) usually occurs after a
variable period of prodromic symptoms and the im-
portance of early detection and treatment of first-
episode schizophrenia has been raised in psychiatric
literature from long time (7). In fact, it has been sug-
gested that the first years of the schizophrenic disor-
der may be a critical period for long-term prognosis,
as the relationship between the delay in treatment of
FES and poorer outcome is well demonstrated (8).
Long-acting injectable antipsychotics (LAIs) have
been commonly considered as an adherence inter-
vention for patients who are ‘non-compliant’ with the
oral medication they have been prescribed (9). In par-
ticular, there are some concern of their use as a first-
line treatment in FES, and this may be particularly
true for first generation LAIs, that are burdened by
several adverse effects (such as extrapyramidal side
effects, tadive diskynesia and QT prolongation) (10).
However, the availability of the second-generation
long-acting injectable antipsychotics (SGAs-LAIs)
represents an advance in the long-term management
of schizophrenia, particularly regarding subjective tol-
erability (11). In fact, SGAs-LAIs have been shown to
have at least equal or even superior efficacy and to
be associated with less propensity to induce parkin-
sonism and tardive diskynesia compared with first
generation LAIs, although some SGAs-LAIs may be
associated with an increased incidence of metabolic
side effects (12). 
Interestingly, another point in favour of SGAs-LAIs
could be their potential efficacy in problematic pa-
tients with schizophrenia such as those in comorbidity
with alcohol and substance use disorder. This aspect
has been recently reported in some studies. Risperi-
done long-acting injection (RLAI) was more effective
than zuclopenthixol-depot in improving substance
abuse and schizophrenia symptoms in subjects with
dual diagnosis (13). This observation was confirmed
also by Meredith et al. (14).
Currently, in Italy, there are four available SGAs-LAIs
(Tab. 1):  RLAI, paliperidone palmitate (PLAI), olan-
zapine pamoate (OLAI) and aripiprazole. In the pre-
sent review the literature on SGAs-LAIs in the treat-
ment of FES will be reviewed and practical advice will
be given concerning the use of these drugs in the
everyday “real world” clinical practice.
Schizophrenia is associated with poor medication
adherence: is this mostly true for first episode?
It is generally recognized that treatment non-adher-
ence is a remarkable problem in the management of
patient with schizophrenic disorder, with reported dis-
continuation rates more than 50% in several studies
(15-17). It has been demonstrated that adherence
with oral conventional and/or atypical antipsychotics
is poor in both short and long term (18) and is associ-
ated with relapse, even if it is unclear whether non-
adherence precedes the relapse or is a consequence
of it (19-21). In the Clinical Antipsychotic Trials for In-
tervention Effectiveness (CATIE) trial (22) the 74% of
patients discontinued the treatment prematurely.
Moreover, in the European First Episode Schizophre-
nia Trial (EUFEST) about 40% of patients discontin-
ued their treatment within one year after the onset of
the disorder (23).
In FES, there are a couple of variables that may co-
operate in causing nonadherence (24, 25). The most
common are the lack of insight, the sensation of a
subjective distress as a result of side effects, the fear
of potential side effects and the poor medication effi-
cacy with symptoms’ persistence (26-28). However,
above all, one of the main factor associated with non
adherence may be the wrong belief that treatment is
no longer needed after few weeks or months, espe-
cially (and paradoxically) in presence of a perceived
improvement (29). Furthermore, the comorbidity with
substance abuse, the lack of a familiar and social ef-
fective support, the failure of therapeutic alliance, the
complexity of some treatment regimens and, last but
not least, the perceived stigma that is still associated
with psychiatric disorders and antipsychotic treat-
ment, may further contribute to non-adherence (30-
34).
It has been demonstrated that neurocognitive dys-
functions are important predictors for non-adherence
in patient with schizophrenia (35). The importance of
cognitive deficits in schizophrenia is highlighted by
reports indicating that the severity of cognitive deficits
is predictive of treatment compliance, adherence, and
risk of relapse among FES individuals (36-38). More-
over, social cognition appears to be compromised in
all FES patients compared to healthy controls and
this may be also a predictor of non adherence (39).
Even in case of successfully treatment of FES, the
eventual non-adherence may be associated not only
with relapse, but also with an increased mortality (40,
41). In fact, treatment nonadherence after the FES
may be associated with increased suicide rates and
death for consequences of medical illnessess such
as diabetes, cardiovascular disorders, cancer and
stroke (42-44). As stated by Kane (45)  “…clinicians
should educate patients about adherence and consid-
er treatment options that will improve adherence. Re-
covery is attained when patients experience symptom
remission, vocational role fulfillment, independent liv-
ing, and social relationships for at least 2 years”.
Moreover, it has been demonstrated that SGAs-LAIs
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treatment may reduce the suicide risk in patient with
schizophrenia, simply improving adherence. Ascher-
Svanum et al. (46) demonstrated that OLAI was as-
sociated with a significantly lower incidence of psy-
chiatric hospitalization due to suicide threats. Howev-
er, most studies investigating incidence and predic-
tors of suicide and mortality in patients with FES have
relatively short follow-up intervals and, to date, no da-
ta have been published concerning the reduction of
suicide risk with SGAs-LAIs treatment. 
Therefore, the availability of SGAs-LAIs may be a
favourable treatment option and should be consid-
ered since the first episode and not only at the last
stages of schizophrenia (47). As argued by Stephen
Stahl (48),  “shall the last be first?”. 
Current guidelines on LAIs use in first-episode
Schizophrenia
In 1998, the first published guidelines recommended
that conventional LAIs should be considered for any
patients with schizophrenia when a long-term treat-
ment was necessary (49). 
More recently, the American Psychiatric Association
(50) recommended LAIs for patients with recurrent re-
lapses related to partial or full nonadherence, but not
explicitally as a first-line treatment in FES. In line with
APA guidelines, also the Canadian Psychiatric Asso-
ciation Clinical Practice Guidelines (51) recommend-
ed LAIs to lower nonadherence in patients with recur-
rent and multiple episodes and/or with persistent pos-
itive symptoms. Also the International Psychophar-
macology Algorithm Projects (IPAPs) schizophrenia
algorithm (http://www.ipap.org/schiz/) proposed the
utilization of LAIs in patients with partial or complete
noncompliance: again, there is no explicit recommen-
dation on their use as a first-line treatment in FES,
but one can argue that, implicitally, in case of non ad-
herence, they may be accordingly used. On the other
hand, the National Clinical Excellence (NICE) guide-
lines (52) recommend that LAIs (especially SGAs-
LAIs) may be given after an acute episode of schizo-
phrenia if the patient prefers and to avoid covert non-
adherence to oral medication. This was also the ad-
vice of the World Federation of Societies of Biological
Psychiatry (53). Also the PORT Recommendations
(54) proposed that “long-acting injection antipsychotic
medication maintenance treatment should be avail-
able and considered for persons who have a history
of frequent relapse on oral medication, or a history of
problems with adherence on oral medication, or who
prefer the long-acting injection depot regimen”.
In general, the current guidelines on schizophrenia
treatment consider LAIs as drugs of choice for long-
term therapy in patients who are nonadherent with
antipsychotic medication and the use of such medica-
tions, especially SGAs-LAIs, may represent a promis-
ing strategy that should be employed in such patients
to achieve symptoms’ remission, prevent relapse and
reduce all-causes mortality (55). Thus, even not for-
mally declared, it can be argued that, implicitally, in
all cases of non adherence in FES, the LAIs (prefer-
ably SGAs-LAIs) may be consequently used.
Psychiatrists’ attitude toward LAIs use in the first
episode of schizophrenia
Despite the effectiveness of LAIs in the treatment of
schizophrenia, sometimes psychiatrists’ attitude to-
ward these agents is negative, especially in the treat-
ment of FES (56, 57). In fact, concerning FES, some
of the common reasons against early usage of LAIs
are the long-established association of depot treat-
ment as a coercive and stigmatizing therapy, the rec-
ommendation of guidelines to use first oral antipsy-
chotics, the belief that a good therapeutic relationship
may be a pro-adherence factor, the relative lack of
long-term studies and the tolerability profile of LAIs
(58). Although LAIs were recognized to be adher-
ence-enhancing and strongly preventive of relapse, a
great number of psychiatrists seemed to avoid pre-
scribing depot antipsychotics especially for patients
with FES (59). Psychiatrists frequently imagine that
patients with FES would not accept depot antipsy-
chotics and that depots are generally eligible for
chronic patients (60). However, it should be argued
that these belief are often not supported by scientific
evidences that, instead, point out the need of ensur-
ing adherence after FES even with the use of LAIs
(61).   
Moreover, lack of knowledge, misperceptions and
stigma related to LAIs and other treatment options
should be addressed by providing patients with accu-
rate information (62). Psychiatrist should avoid mak-
ing assumptions about patients’ attitudes to LAIs as
even if these attitudes vary, some FES patients not
prescribed LAIs are favorable to considering this
treatment (63). However, depot antipsychotics pre-
scribing should always result from a shared decision-
making process in which clinicians and patients ex-
plicitly discuss the pros and cons of different formula-
tions and drugs (57). 
Llorca et al. (64) selected 53 French psychiatrists
working in the “real world” clinical practice and con-
sidered to be experts in the use of LAIs and submit-
ted to them a questionnaire consisting of 32 ques-
tions that covered 539 therapeutic options grouped
into 3 areas that were judged as essential: 1) Target-
population: Description of the different indications of
the LAI antipsychotics and of the most appropriate
period of the illness to introduce the treatment. 2)
Prescription and use: Choice of the molecule, meth-
ods of introduction, specific strategies depending on
the psychiatric disorder or co-morbidities, and treat-
ment monitoring. 3) Specific population: Use of LAI
antipsychotics in pregnant women, elderly patients,
subjects in a precarious situation, and subjects hav-
ing to be treated in a prison establishment. Results
showed that, in an evidence-based clinical approach,
psychiatrists, through shared decision-making, should
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quire long-term antipsychotic treatment an LAI an-
tipsychotic as a first-line treatment. In particular,
SGA-LAIs were recommended as maintenance treat-
ment after the first episode of schizophrenia whereas
first-generation LAIs were not recommended in the
early course of schizophrenia.
However, it should be specified that, in some pa-
tients, a decision not to consider LAIs may be more
suitable. As pointed out by Kane and Garcia-Ribera
(65), this may be particularly true in: 1) patients who
has consistently demonstrated his or her ability to
take oral medication and chooses to continue doing
so, 2) patients who regardless of adequate discus-
sion of potential benefits and risks, and sufficient psy-
choeducation regarding the nature of the illness, ob-
stinately refuses even to try a LAI and 3) patient un-
able to tolerate or unresponsive to the drugs avail-
able in LAI formulations.
SGAs-LAIs in the treatment of first episode in pa-
tients with schizophrenia
The successful treatment of FES is essential to im-
prove long-term outcomes, as it has been demon-
strated that the majority of clinical and psychosocial
deterioration with cognitive impairment and increas-
ing structural changes in brain volume take place
within the first five years from the disorder’ onset
(66). In FES, pharmacological intervention favourably
affect symptomatic control and functional outcomes
and, therefore, the primary objective of treatment dur-
ing this phase is to prevent relapses, possibly restor-
ing the socio-occupational functioning to the premor-
bid level (67).  
However, as above described, poor medication ad-
herence is particularly common in FES and the most
important goal should be the improvement of medica-
tion adherence. In a Finnish cohort study (68) con-
ducted on 2588 FES patients, it was demonstrated
that fewer than 50% of patients in the Finnish health-
care system continued treatment for the first two
months after their first hospitalization. Grippingly, the
type of administration affected relapse and LAIs had
a 64% lower relapse rate than the equivalent oral
treatment. Regarding which LAI may be more appro-
priate for FES, there is, to date, a relative lacking of
long-term RCTs comparing LAIs with oral medication
regarding effectiveness, tolerability, relapse preven-
tion and overall outcomes (69, 70). Research sup-
porting the usefulness of SGA-LAIs in FES has been
mainly performed using RLAI since RLAI was the first
marketed SGA-LAI and, therefore, the most evidence
in the treatment of FES concerns it (Tab. 2).
Risperidone long-acting injection (RLAI)
RLAI represents the first long acting formulation of
second-generation antipsychotic drugs, launched in
North America in 2004, available for the treatment of
schizophrenia and closely related psychiatric condi-
tions (71). Several studies demostrated that RLAI ad-
ministered once every 2 weeks, has notably efficacy
and well tolerated in both schizophrenia and schizoaf-
fective disorder patients (72-77). Due to its tolerabili-
ty, RLAI is an important antipsychotic treatment avail-
able for use in vulnerable groups of patients, as el-
derly patients with psychosis (78). Compared to oral
atypical and conventional long-acting agents, RLAI
reduced the numbers of relapses in schizophrenia
patients (79-82). In addiction, concomitant medica-
tions as anticholinergics, anxiolytics, hypnotics, seda-
tives, antipsychotics used in combination, antidepres-
sants and mood stabilizers were reported to be re-
duced in use (38, 83). For its favourable profile, it
may be a rational choice for patients with FES or in
the early phases of schizophrenia as demonstrated
by Parellada et al. (84), Lasser et al. (85), Naprye -
yenko et al. (86) and Malla et al. (87). 
Specifically concerning FES, Kim et al. (88) conduct-
ed a prospective, naturalistic, controlled, and open-la-
bel study over two years in 50 patients with FES. 22
patients with schizophrenia were assigned to the
RLAI group and 28 patients with schizophrenia to the
oral risperidone group as control. RLAI group showed
significantly lower relapse rate and higher medication
adherence than the control group. On the other hand,
Emsley et al. (89, 90) evaluated the efficacy of RLAI
(25-50 mg per every two weeks) among 50 patients
with FES and 36 of these (72%) completed the trial,
suggesting a relatively low discontinuation rate. A re-
duction of at least 50% on the PANSS total score was
obtained by 42 of the 50 FES patients (84%) and 32
patients (64%) met the Remission in Schizophrenia
Working Group (RSWG) remission criteria. 31 pa-
tients (97%) among that 32, maintained this remis-
sion status for two years until the completion of the
study. Weiden et al. (91) conducted a prospective
randomized controlled trial to compare acceptance
and adherence between RLAI and continued oral an-
tipsychotics (such as haloperidol, olanzapine, queti-
apine and risperidone) in FES. Patients who were
treated with RLAI were significantly more adherent
than patients who were taking oral antipsychotics. 
More recently, Bartzokis et al. (92) evaluated the
treatment effects of RLAI on frontal lobe white matter
volume in FES patients in a randomized 6-month trial.
Researchers, using inversion recovery magnetic res-
onance imaging, showed that the frontal lobe white
matter volume was stable in the RLAI group whereas
it significantly decreased in the oral risperidone
group. This finding suggests that RLAI can improve
the trajectory of myelination in FES patients and may
be related with positive effects on cognitive functions
and processes. Moreover, Tiihonen et al. (65) con-
ducted a nationwide cohort study in Finland between
2000 and 2007 and evaluated 2588 patients with
schizophrenia hospitalized for the first time. They
found the RLAI or depot formulations were associat-
ed with a 50-65% reduced rehospitalisation rate com-
pared to the identical medication in oral form. On the
other hand, Weiden et al. (93) have also demonstrat-
Research and Advances in Psychiatry 2015; 2(2):48-5852
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ed that acceptance of RLAI was associated with an
initial adherence benefit that was not sustained over
time. However, they also observed that. Even if non-
adherence was almost universal in first-episode co-
hort, nonadherence was more easily detected among
FES patients treated with RLAI therapy than it was
with oral antipsychotics.
Other SGAs-LAIs
Fu et al. (94), in a post-hoc, subgroup analysis of a
13-week, double-blind, double-dummy, multicenter
study, evaluated patients recently diagnosed with
schizophrenia (≤ 5 years) who were administered
PLAI or RLAI. They found that the tolerability and effi-
cacy of PLAI and RLAI were generally similar over 13
weeks. 
To date, no studies were present concerning OLAI
and aripiprazole long-acting in the treatment of early
schizophrenia or FES. 
Conclusions
All SGA-LAIs have been approved for long-term treat-
ment of patients with schizophrenia (95). Potential
advantages and disvantages of SGA-LAIs in the
treatment of FES in everyday clinical practice are
summarized in Table 3. On the basis of existing liter-
ature, it can be argued that the usage of SGA-LAIs in
first-episode schizophrenia may have beneficial im-
pacts on treatment outcomes, but, to date, evidences
are limited to RLAI. Due to its efficacy and tolerability,
RLAI is an important antipsychotic treatment avail-
able for use in at-risk group of patients, such as FES
patients. Especially in terms of adherence and re-
lapse prevention, prescribing other SGA-LAIs might
be another treatment option even in FES, when RLAI
is not indicated, but no evidences still exist. In fact,
there is limited research data (focused only on RLAI)
for clinical trials in FES. More well-designed, random-
ized controlled clinical trials for the use of SGA-LAIs
in FES are undoubtely needed.
Research and Advances in Psychiatry 2015; 2(2):48-5854
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Table 3 - Summary of potential pros and cons of SGA-LAIs in FES as compared to oral antipsychotics. 
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> OLAI > Aripiprazole) may be considered when choosing 
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RLAI is the most studied SGA-LAI in FES RLAI needs refrigeration with appropriate storage 
Less loss of frontal lobe white matter volume observed 
with RLAI after FES 
 
Patients with a lower functioning may prefere a SGA-LAI  
Relatively good safety profile and tolerability  
May guarantee a regular contact between the patient and 
the psychiatrist after FES 
 
Allows healthcare professionals to be alerted and to 
intervene properly if patients fail to take their medication 
after FES 
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